Enovix Cut to Market Perform as Shares Slide 28.9 Percent

Enovix Corporation (NASDAQ: ENVX) trades at $1.80, down 28.9 percent, after Oppenheimer cut the battery maker from "outperform" to "market perform" in a report released on Friday, according to Briefing.com.

The downgrade did not arrive alone. It followed a sequence of analyst revisions that tightened through the autumn:

• October 13: Northland Securities set a $4.00 price objective.
• October 5: TD Cowen upgraded the stock to "hold."
• October 2: Weiss Ratings reissued a "sell (e+)" rating.
• August 17: William Blair lowered Enovix from "outperform" to "market perform."
• August 14: Canaccord Genuity cut its price objective from $12.00 to $8.00 but kept a "buy" rating.

MarketBeat data show the consensus now sits at "Hold," with an average price target of $7.80 — more than four times the current share price. That gap deserves scrutiny. One analyst rates the stock Strong Buy, three rate it Buy, six Hold and two Sell. A $7.80 average against a $1.80 print suggests several of those targets predate the collapse; the consensus number flatters what the desk action actually says.

What do the balance-sheet numbers show?

The Friday opening price of $1.80 sits at the bottom of a 52-week range that runs from $1.78 to $9.19. The 50-day moving average is $2.82; the 200-day average is $4.93. Both confirm a sustained decline, not a one-week shock.

Other figures:

• Market capitalization: $395.01 million.
• Price-to-earnings ratio: -2.22.
• Beta: 2.34.
• Current ratio: 9.71; quick ratio: 9.37; debt-to-equity: 2.46.

Liquidity looks strong on its face. The near-1,000-percent net margin figure below explains why the debt line and the cash line both matter more than usual here.

What did the last quarter report say?

On Friday, November 13, Enovix reported quarterly earnings of ($0.15) per share, beating the consensus estimate of ($0.20) by $0.05. Revenue came in at $11.04 million. Return on equity stood at negative 64.50 percent, and the net margin at negative 473.89 percent. Analysts forecast full-year earnings per share of -$0.79.

A five-cent beat on a twenty-cent loss is a narrow cushion. The revenue line is the harder one: Enovix guided fourth-quarter revenue to $9 million–$10 million, below the $11.04 million it just reported. Sequential contraction in a company valued on growth is the number investors should weigh first.

The company did strengthen its balance sheet. It held $512.2 million in cash and related holdings at quarter-end and retired $128 million in face value of convertible notes for approximately $81.4 million — retiring debt at 64 cents on the dollar. Buying back paper below par is real value creation. It does not, by itself, produce revenue.

What is not in the ratings?

Two law firms announced investigations into whether Enovix misled investors about the readiness of its AI-1 silicon-anode cells for phone qualification. These are investigations, not findings of wrongdoing. Neither Oppenheimer nor the consensus table prices that risk explicitly, and the allegations touch the growth story — smartphone qualification — that underpins the bull case.

Institutional investors own 50.92 percent of the stock, and several built positions in the second quarter: BlackRock Inc. at $100,054,000; Connor Clark & Lunn Investment Management at $8,689,000; Bank of America at $8,356,000; Bank of New York Mellon at $3,551,000; and Deutsche Bank at $3,343,000. Those are second-quarter entries, made before the third-quarter report and the current price.

Enovix develops lithium-ion batteries with a silicon-based anode and a proprietary three-dimensional cell architecture, targeting smartphones, wearables, laptops, augmented- and virtual-reality products, and defense and industrial markets.

Cash of $512.2 million buys time; guidance of $9 million to $10 million buys questions.